home / stock / lexxw / lexxw news

LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 07/26/21

Stock Information
Company Name: Lexaria Bioscience Corp. Warrant
Stock Symbol: LEXXW
Market: NASDAQ
Website: lexariabioscience.com
Menu
LEXXW LEXXW Quote LEXXW Short LEXXW News LEXXW Articles LEXXW Message Board
Get LEXXW Alerts

News, Short Squeeze, Breakout and More Instantly...
LEXXW - Lexaria Receives US$3,817,643 From Warrant Exercises

(TheNewswire) Kelowna, British Columbia - TheNewswire – July 26, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms i...
LEXXW - Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

(TheNewswire) All objectives evaluating DehydraTECH TM drug delivery platform successfully achieved Kelowna, British Columbia - TheNewswire – July 22, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (th...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Significantly Enhanced Delivery of Colchicine

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. According to the update, the study demonstrated that DehydraTECH(TM)-enabled ...

LEXXW - Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its to...
LEXXW - Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada's National Research Council

(TheNewswire) VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs Kelowna, British Columbia - TheNewswire – July 15, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “C...

LEXXW - Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council

VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce results f...

LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced an additional expansion of its intellectual property (“IP”) portfolio with its first-ever patent granted in Japan. According to the update, “Stable ready-to-d...
LEXXW - Lexaria Receives Patent Protection in Japan

(TheNewswire) New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia Kelowna, British Columbia, July 13, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company ...

LEXXW - Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily d...

LEXXW - Lexaria Announces 2021 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting'). On June 28, 2021 at 1:00 p.m. (Pacific Time)...
Previous 10 Next 10